Anthracycline-Induced Cardiotoxicity in Adult Hematologic Malignancies

Seminars in Oncology

Volumn 33, Issue SUPPL. 8, 2006, Pages 22-27

  Johnson, S A ^a  

^a TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTHRACYCLINE; ANTIINFECTIVE AGENT; BLEOMYCIN; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOSINE; DACARBAZINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; FLUDARABINE; IDARUBICIN; IFOSFAMIDE; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; MITOXANTRONE; PLATINUM; PREDNISOLONE; RAZOXANE; RITUXIMAB; STEROID; THALIDOMIDE; VINBLASTINE; VINCRISTINE;

ARTICLE; BONE MARROW TRANSPLANTATION; CANCER PATIENT; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; HEALTH CARE COST; HEART INJURY; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; MEDICAL SPECIALIST; MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; STEM CELL TRANSPLANTATION;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CAUSE OF DEATH; HEART; HEART DISEASES; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA; LYMPHOMA; MULTIPLE MYELOMA; RETREATMENT;

EID: 33744966574     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.04.021     Document Type: Article

References (31)

1. Johnson S.A., and Richardson D.S. Anthracyclines in haematology. Pharmacokinetics and clinical studies. Blood Rev 12 (1998) 52-71
2. Yates J., Glidewell O., Wiernik P., et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia. A CALGB study. Blood 60 (1982) 454-462
3. Rowe J.M., and Tallman M.S. Intensifying induction therapy in acute myeloid leukemia. Has a new standard of care emerged?. Blood 90 (1997) 2121-2126
4. The AML Collaborative Group. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haematol 103 (2006) 100-109
5. Bonadonna G., Monfardini S., De L.M., et al. Phase I and preliminary phase II evaluation of adriamycin (NSC 123127). Cancer Res 30 (1970) 2572-2582
6. Coltman Jr. C.A. Adriamycin (NSC-123127) in the treatment of lymphomas. Southwest Oncology Group Studies. Cancer Chemother Rep 6 (1975) 375-380
7. Bonadonna G., DeLena M., Monfardini S., et al. Combination usage of adriamycin (NSC-123127) in malignant lymphomas. Cancer Chemother Rep 6 (1975) 381-388
8. Barlogie B., Smith L., and Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310 (1984) 1353-1356
9. Minotti G., Menna P., Salvatorelli E., et al. Anthracyclines. Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56 (2004) 185-229
10. Lefrak E.A., Pitha J., Rosenheim S., et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32 (1973) 302-314
11. Von Hoff D.D., Layard M.W., Basa P., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91 (1979) 710-717
12. Swain S.M., Whaley F.S., and Ewer M.S. Congestive heart failure in patients treated with doxorubicin. A retrospective analysis of three trials. Cancer 97 (2003) 2869-2879
13. Lipshultz S., Rifai N., Sallan S.E., et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 96 (1997) 2641-2648
14. Shan K., Lincoff A.M., and Young J.B. Anthracycline-induced cardiotoxicity. Ann Intern Med 125 (1996) 47-58
15. Limat S., Demesmay K., Voillat L., et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol 14 (2003) 277-281
16. Anderlini P., Benjamin R.S., Wong F.C., et al. Idarubicin cardiotoxicity. A retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 13 (1995) 2827-2834
17. Nousiainen T., Jantunen E., Vanninen E., et al. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer 86 (2002) 1697-1700
18. Kremer L.C., van Dalen E.C., Offringa M., et al. Anthracycline-induced clinical heart failure in a cohort of 607 children. Long-term follow-up study. J Clin Oncol 19 (2001) 191-196
19. Lipshultz S.E., Colan S.D., Gelber R.D., et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324 (1991) 808-815
20. Aviles A., Arevila N., az Maqueo J.C., et al. Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults. Leuk Lymphoma 11 (1993) 275-279
21. Weinstein D.M., Mihm M.J., and Bauer J.A. Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. J Pharmacol Exp Ther 294 (2000) 396-401
22. Hequet O., Le Q.H., Moullet I., et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 22 (2004) 1864-1871
23. Brockstein B.E., Smiley C., Al-Sadir J., et al. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer. Prognostic factors. Bone Marrow Transplant 25 (2000) 885-894
24. Robin M., Guardiola P., Dombret H., et al. Allogeneic bone marrow transplantation for acute myeloblastic leukaemia in remission. Risk factors for long-term morbidity and mortality. Bone Marrow Transplant 31 (2003) 877-887
25. Stevenson L.W. Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart Fail 1 (1999) 251-257
26. Jensen B.V., Skovsgaard T., and Nielsen S.L. Functional monitoring of anthracycline cardiotoxicity. A prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 13 (2002) 699-709
27. Stewart A.L., Greenfield S., Hays R.D., et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA 262 (1989) 907-913
28. Dracup K., Walden J.A., Stevenson L.W., et al. Quality of life in patients with advanced heart failure. J Heart Lung Transplant 11 (1992) 273-279
29. Juenger J., Schellberg D., Kraemer S., et al. Health related quality of life in patients with congestive heart failure. Comparison with other chronic diseases and relation to functional variables. Heart 87 (2002) 235-241
30. Duggan D.B., Petroni G.R., Johnson J.L., et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease. Report of an intergroup trial. J Clin Oncol 21 (2003) 607-614
31. Desikan R., Jagannath S., Richardson P., et al. Multiple myeloma and otherplasma cell dyscrasias. In: Pazdur R., Coia L.R., Hoskins W.J., and Wagman J. (Eds). Cancer Management. A Multidisciplinary Approach. (2003), Oncology Group, New York 727-746